Ofatumumab Recruiting Phase 4 Trials for Multiple Sclerosis / Coronavirus Disease 2019 (COVID‑19) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT04869358Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab